How to Prepare Performance Verification Dossiers for Medical Device Registration in Australia?

For medical devices seeking registration in Australia, performance verification documentation is a core component of the technical file that directly influences whether the product will receive approval from the Therapeutic Goods Administration (TGA). Companies must first determine whether the product falls within the scope of Australian medical device regulation, then identify the regulatory pathway based on risk classification (Class I, IIa, IIb, III). Performance verification should cover basic safety, performance specifications, biocompatibility, and electromagnetic compatibility (where applicable). Existing test reports from NMPA, CE, FDA, or MDSAP certifications can be largely reused, but attention must be paid to differences in Australian standards and localization requirements (e.g., 230V/50Hz mains testing). Common risks include outdated ISO/IEC standard versions, failure to address TGA's additional requirements for special materials (e.g., drug-eluting or biological components), and insufficient statistical justification of sample sizes. To mitigate these risks, manufacturers should conduct a gap analysis of existing technical documentation and engage laboratories with OECD GLP or ISO 17025 accreditation for supplementary testing. The local agent (Sponsor) is responsible for submitting the application and post-market obligations, so performance verification reports must be authentic, complete, and traceable.

Key Summary

Performance verification documentation is the core of the technical file for Australian medical device registration and directly affects TGA approval. The initial steps are to determine whether the product is a regulated medical device in Australia and to classify it (Class I, IIa, IIb, III) to select the correct registration route. Performance verification must cover basic safety, performance specifications, biocompatibility, and electromagnetic compatibility (if applicable).

• For products already certified under NMPA, CE, FDA, or MDSAP, most test reports can be reused, but differences in Australian standards and localization requirements (e.g., 230V mains testing) must be considered.
• Common risks include using outdated ISO/IEC standard editions, omitting TGA-specific requirements for special materials (e.g., drug-eluting or biological components), and failing to provide sufficient statistical sample size justification.
• Conduct a gap analysis of existing technical files and commission laboratories with OECD GLP or ISO 17025 accreditation to perform supplementary tests.
• The local agent (Sponsor) is responsible for dossiers submission and post-market obligations; therefore, performance verification reports must be authentic, complete, and traceable.

Applicable Scenarios and Core Issues

Performance verification documentation is a critical component of the Australian technical file and demonstrates that the device meets relevant Australian standards and safety/performance requirements. Any medical device intended for supply in Australia, regardless of risk classification, must be supported by adequate performance verification evidence. The central questions are: how to efficiently plan testing or repurpose existing data in line with TGA’s review expectations; whether all testing must be performed locally in Australia; and whether reports from CE, FDA, or NMPA can be directly reused. Mishandling these issues can lead to extended correction cycles, higher costs, or even registration failure.

Australia is a member of GHWP, and its registration requirements are highly harmonized with the IMDRF framework, yet they retain specific domestic features. For example, Class I non-sterile, non-measuring devices may not require TGA pre-market assessment, but a technical file must still be available for audit. Class IIa and above require full assessment. Performance verification should cover basic safety (e.g., electrical safety), performance specifications (e.g., accuracy, sensitivity), biocompatibility, and stability (shelf life, transport simulation). Active devices additionally require electromagnetic compatibility (EMC) testing. Software as a Medical Device (SaMD) must provide verification and validation reports as well as cybersecurity evidence.

Registration Determination Logic

The following seven-step logic helps establish the correct regulatory pathway:

• Step 1: Determine whether the product meets the definition of a medical device in Australia. If it is an IVD, follow IVD regulations.
• Step 2: Determine the classification using the Classification Rules.
• Step 3: Select the registration path based on classification: Class I non-sterile/non-measuring products can self-assess; Class I sterile/measuring, IIa, IIb, and III require TGA assessment.
• Step 4: Assess whether existing quality system certificates (e.g., ISO 13485, MDSAP) and technical documentation can be reused.
• Step 5: Identify additional performance verification tests needed, especially in relation to Australian standard variations (e.g., AS/NZS standards).
• Step 6: Appoint a local agent (Sponsor) responsible for submissions, communication, and post-market obligations.
• Step 7: Compile a complete technical file including performance verification summaries, test reports, risk management reports, and, if applicable, integrate with MDSAP, CE, or other market reports.

For multi-country registration projects, prioritize core tests (e.g., ISO 10993 biocompatibility, IEC 60601 series) and use internationally recognized standards to minimize duplicate testing. Australia accepts FDA or CE test reports, but you must confirm that the specific standard versions are accepted by TGA. If discrepancies exist, gap testing or declarations may be required.

Documentation and Evidence

The performance verification file should include the following core elements:

• Product description and intended purpose.
• Performance specifications and acceptance criteria (e.g., accuracy, repeatability, sensitivity).
• Test methods and standards used (e.g., ISO, IEC, AS/NZS, GB).
• Test reports issued by competent laboratories (e.g., ISO 17025, OECD GLP).
• Sample size justification with statistical reasoning.
• Biocompatibility evaluation (recommended ISO 10993 series).
• Stability test reports (accelerated aging, real-time aging, transport simulation).
• Software verification and validation (if applicable, including cybersecurity).
• Electrical safety and electromagnetic compatibility reports for active devices.
• Risk management report (ISO 14971) linking performance verification results to risk control measures.
• Comparisons with similar devices (clinical evaluation or performance comparison data may be cited).

Evidence management must comply with TGA’s “hierarchy of evidence,” which prioritizes clinical data over animal studies and non-testing methods (e.g., simulation, theoretical analysis). Performance test reports should include raw data, test conditions, equipment information, and signed approvals. All non-English documents must be accompanied by certified translations.

Common Mistakes

• Directly using CE or FDA reports without verifying whether the standards version is accepted by TGA, leading to requests for retesting.
• Overlooking Australia-specific electrical requirements (e.g., 230V/50Hz mains testing) and failing to perform voltage adaptation tests.
• Biocompatibility testing not covering all patient-contacting materials or using obsolete standards (e.g., ISO 10993-1:2009 instead of the latest edition).
• Software devices lacking adequate verification and validation documentation, especially cybersecurity risk assessment.
• Insufficient sample sizes or missing statistical justification, forcing supplementary testing.
• Stability testing relying only on real-time aging without considering transport vibration simulation (e.g., ISTA standards).
• Submitting reports from non-GLP or non-ISO 17025 laboratories, raising data reliability concerns.
• Confusing “performance verification” with “design verification” and lacking acceptance criteria linked to performance specifications.

Company Preparation Checklist

• Confirm product classification and the applicable standards list (AS/NZS and ISO/IEC).
• Organize existing test reports and perform a gap analysis to identify missing test items.
• Appoint a local agent (Sponsor) and sign the service agreement.
• Commission laboratories for supplementary testing and ensure their qualifications are compliant.
• Prepare a performance verification plan including test items, sample sizes, and acceptance criteria.
• Execute tests and obtain complete reports (including raw data).
• Write a performance verification summary and link it to risk management documents.
• Translate non-English documents (if any) and have them notarized.
• Prepare the technical file structure according to TGA eSubmit or paper requirements.
• Review the completeness and consistency of all documents before submission.
• Prepare answers for on-site inspections or document audits.

AIMEILI Regulatory Interpretation and Business Impact

The most common misjudgment in Australian registration is assuming CE or FDA reports can be “directly transferred.” In fact, TGA has specific expectations for standard versions, test conditions, and sponsor responsibilities. At the project outset, complete a gap analysis with particular focus on: whether the standard edition is accepted by TGA (e.g., AS/NZS 3200.1 replacing an earlier IEC 60601-1 edition), whether biocompatibility covers all contact materials, and whether EMC testing for active devices reflects the Australian grid environment.

Reusable documents include ISO 13485 certificates, risk management reports, biocompatibility testing conducted to the latest ISO 10993, and basic performance testing based on international standards. Elements that require localization include: electrical safety testing supplemented to AS/NZS standards, software validation with cybersecurity risk assessment, and labeling/instructions for use compliant with TGA labeling rules. The local agent (Sponsor) is critical—they submit the application, pay annual fees, handle adverse event reports, and assist TGA with inspections.

For manufacturers planning multi-country registration, we recommend using the MDSAP framework as the overarching structure for consolidating performance verification dossiers. This approach simultaneously satisfies Australia, Canada, Brazil, Japan, and the United States, thereby reducing the risk of duplicate work and correction cycles. From a business impact perspective, early identification of gaps and proper use of existing data can significantly shorten time-to-market and lower registration costs for the Australian market.

Common Follow-up Questions

Q: Does Australia accept NMPA performance test reports from China?

A: The TGA does not directly accept an NMPA registration certificate as performance evidence, but it does accept test reports issued by Chinese laboratories that are accredited to ISO 17025 or GLP. The test standards should preferably be international (ISO/IEC). If GB standards are used, a standard equivalence justification must be provided. The report must include raw data and an English translation.

Q: Do Class I devices need to submit performance verification documentation?

A: Class I non-sterile, non-measuring devices can be supplied through “self-assessment” without TGA pre-market review, but a technical file must be maintained for inspection and should still include performance verification evidence. If the Class I device has sterile or measuring functions, it must apply and undergo TGA assessment, and complete performance verification documentation is required.

Q: Must performance verification testing be conducted in Australia?

A: There is no mandatory requirement to test locally in Australia. TGA accepts reports from internationally recognized laboratories (e.g., OECD GLP, ISO 17025, CNAS). It is advisable to choose laboratories with export experience and ensure the reports meet TGA formatting requirements. For specialized tests (e.g., certain cytotoxicity tests in biocompatibility), internationally accepted methods suffice.

Implementation Recommendations

In practice, manufacturers should break the task into five workstreams: regulatory determination, documentation preparation, evidence reuse, localization conversion, and post-market maintenance. This prevents ad hoc file compilation by a single department and enables sales, R&D, quality, and regulatory teams to align on the target country’s requirements early.

If entering multiple markets concurrently, first establish a unified core technical file, then supplement country-specific authorization, labeling, language, forms, and local agent documentation. Efficiency in multi-country registration often depends on whether the initial document framework is unified, rather than the speed of submission to each country.

• First confirm whether the product falls within the regulatory scope of the target country’s medical device regulation.
• Confirm the risk classification, registration pathway, and application entity.
• Verify that the technical file, quality system, and clinical evidence support one another.
• Clarify the local agent, authorized representative, and certificate control rights.
• Establish post-market change, renewal, and vigilance event maintenance mechanisms.